Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699515 | 0.82 | MMP1 (0.52) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL13912226 | 0.82 | MMP1 (0.52) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL11527770 | 0.82 | MMP1 (0.52) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL2313350 | 0.81 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL27118233 | 0.80 | USP2 (0.52) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL9966033 | 0.80 | MMP1 (0.50) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL1582575 | 0.80 | CNR1 (0.40) | ALDH1A1KMT2AMEN1ACACB | |
| SCHEMBL2314196 | 0.80 | MMP1 (0.46) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL8224748 | 0.80 | MMP1 (0.50) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL12583433 | 0.78 | MEN1 (0.38) | MMP1MMP2MMP3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194778-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LTD (GB) | 2017-01-18 | — | — | EP | claimed |
| US-20110190129-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2011-08-04 | — | — | US | claimed |
| EP-2194778-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Syngenta Limited (GB) | 2010-06-16 | — | — | EP | claimed |
| WO-2009027624-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-03-05 | — | — | WO | claimed |
| CN-116590027-A | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal element | JSR株式会社 | 2023-08-15 | — | — | CN | disclosed |
| CN-111849511-B | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal element | JSR株式会社 | 2023-08-08 | — | — | CN | disclosed |
| CN-111849511-A | Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal element | JSR株式会社 | 2020-10-30 | — | — | CN | disclosed |
| CN-106047373-B | Liquid crystal aligning agent | JSR株式会社 | 2020-10-09 | — | — | CN | disclosed |
| EP-2194778-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LTD (GB) | 2017-01-18 | — | — | EP | disclosed |
| EP-2001288-B1 | PROCESS FOR PRODUCING LACTAMIDE COMPOUNDS, NEW LACTAMIDE COMPOUNDS AND FORMULATIONS CONTAINING LACTAMIDE COMPOUNDS | SYNGENTA LTD (GB) | 2015-06-24 | — | — | EP | disclosed |
| CN-101784186-B | Improvements relating to organic compounds | SYNGENTA LTD. (GB) | 2014-10-08 | — | — | CN | disclosed |
| US-8420859-B2 | Formulations | SYNGENTA LIMITED (GB) | 2013-04-16 | — | — | US | disclosed |
| EP-2194778-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Syngenta Limited (GB) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009027624-A3 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| US-20090227453-A1 | FORUMLATIONS | SYNGENTA LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| CN-101404879-A | Process for producing lactamide compound, novel lactamide compound and preparation containing lactamide compound | SYNGENTA LTD (GB) | 2009-04-08 | — | — | CN | disclosed |
| WO-2009027624-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027624-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-03-05 | — | — | WO | disclosed |
| EP-2001288-A2 | PROCESS FOR PRODUCING LACTAMIDE COMPOUNDS, NEW LACTAMIDE COMPOUNDS AND FORMULATIONS CONTAINING LACTAMIDE COMPOUNDS | Syngenta Limited (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007107745-A2 | PROCESS FOR PRODUCING LACTAMIDE COMPOUNDS, NEW LACTAMIDE COMPOUNDS AND FORMULATIONS CONTAINING LACTAMIDE COMPOUNDS | SYNGENTA LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190129-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | NR4A2, NR2C2, CYP4A22 | MMP1 4684/4885MMP2 4139/4885MMP3 3936/4885 |
| US-20090227453-A1 | FORUMLATIONS | CBR3, NR1H3, NR2C2 | MMP1 4739/4885MMP2 4488/4885MMP3 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.